The FDA announced on Wednesday that they have sent "refuse to accept" letters to manufacturers of over 88,000 products containing laboratory-made nicotine.
Stephanie Keith/Getty Images (no translation needed as this is already in standard journalistic English)
Brian Kin, Director of the Center for Tobacco Products, revealed the progress of the FDA's regulation of non-tobacco nicotine sources (i.e. synthetic nicotine). The FDA was authorized earlier this year to regulate synthetic nicotine.
Regulatory gray area.
Brian King stated in a letter to unapproved makers of nasal snuff that "selling or distributing any new tobacco products without pre-market authorization in the U.S. market is illegal." The FDA has not approved any synthetic nicotine products for marketing.
According to regulations set by the FDA, as of July 13th, all unauthorized synthetic nicotine products are considered illegal. Therefore, technically, any manufacturer that has not received FDA approval cannot sell their products after that date.
However, the FDA also noted that it will continue to evaluate over 350 synthetic nicotine products. While many of these products (most of which are e-cigarettes) are technically not allowed to be sold, it is still unclear whether the FDA will remove them from the market upon evaluation. The FDA has exercised enforcement discretion for e-cigarettes containing tobacco-derived nicotine, allowing them to remain on shelves while continuing to weigh their sale.
A buildup process
Jonathan Foulds, a public health science professor specializing in tobacco addiction at Penn State College of Medicine, told Pulse that some manufacturers of synthetic nicotine electronic cigarettes are undoubtedly bad. They exploit regulatory loopholes to stay on the market, with their products mainly targeting teenagers.
Given the tight timeline for compiling evidence, other manufacturers may not have had the opportunity to submit applications to the FDA. "To be honest, I'd be surprised if any of them got authorization," he told Pulse. "It's a lot of work that requires a great deal of information and proper research, which simply can't be completed in just two months." He noted that even electronic cigarette manufacturers that use tobacco-derived nicotine have been unable to meet the FDA's evidence standards, despite having had years to apply for marketing orders.
Statement:
This article is compiled from third-party information and is intended solely for industry exchange and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The purpose of translating this article is solely for industry discussions and research.
Due to limitations in translation ability, the translated article may not fully convey the intended meaning of the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related expressions or positions.
The compilation of information belongs to the original media and author, and in the event of copyright infringement, please contact us for deletion.
He added, "If they are to withdraw from the market during the review by the agency, it would be fine by me, but they should have enough time to tidy up their applications.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
